Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NCT06785324
Recruiting
This clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with Philadelphia Chromosome (Ph) Negative B-ALL undergoing inpatient induction therapy. Participants will take part in 2 different interventions: * Nutrition Intervention * Physical Exercise Intervention All subjects will be provided with a wearable electronic activity monitor (FitBit®) to assist in recording activity levels in minutes of activity.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/18/2025
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL
Register for Updates
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
NCT06953583
Recruiting
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its safety in children and teens who are 2 to 15... Read More
Gender:
ALL
Ages:
Between 2 years and 15 years
Trial Updated:
06/18/2025
Locations: UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California +26 locations
Conditions: Friedreich Ataxia
Register for Updates
Evaluation of the Genetics of Bipolar Disorder
NCT00001174
Recruiting
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Bipolar Disorder
Register for Updates
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
NCT04002947
Recruiting
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma
Register for Updates
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NCT05071937
Recruiting
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT05440929
Recruiting
I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Metastatic Breast Cancer, End of Life
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312
Recruiting
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, in combination with docetaxel, and in combination with paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +14 locations
Conditions: Advanced Solid Tumors
Register for Updates
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
NCT06138873
Recruiting
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise esti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Rush University Medical Center, Chicago, Illinois +4 locations
Conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy
Register for Updates
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356
Recruiting
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles, California +14 locations
Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Register for Updates
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2025
Locations: Chandler Clinical Trials, LLC, Chandler, Arizona +220 locations
Conditions: Alzheimer Disease
Register for Updates
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/17/2025
Locations: Research Site, Glendale, California +22 locations
Conditions: Staphylococcus Aureus
Register for Updates
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167
Recruiting
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: City Of Hope, Duarte, California +4 locations
Conditions: Solid Malignancies, Hematologic Malignancies
Register for Updates